Health TrialsbyHealthPanel

Senolytics for Secondary Progressive MS

ConditionMultiple Sclerosis (MS) Secondary Progressive
Trial statusNot yet recruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age50-85
SponsorOhio State University

About this trial

This is a clinical trial to see whether senolytic therapy is safe and feasible for patients with secondary progressive MS and whether treatment improves physical and thinking abilities. The study seeks to enroll adults with secondary progressive MS (SPMS), aged 50-85, who are not currently taking a MS disease-modifying therapy and have noticed their MS symptoms getting worse. People who join the study will take the medicines dasatinib and quercetin by mouth every two weeks for three months. These medicines work together to remove old, damaged cells that may cause inflammation and slow the repair of nerves. Participants will also be followed for one year from enrollment to monitor for treatment effects.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Individuals aged 50-85 with SPMS diagnosed using the 2024 McDonald Criteria

Not treated with a DMT for MS within the last 6 months or have used alemtuzumab, cladribine, or mitoxantrone.

Evidence of MS progression over the past 12 months.

Disqualifiers

Unstable coronary artery disease (myocardial infarction within 6 months or angina)

Hospitalization within 6 months

Stroke or transient ischemic attack in the past 6 months

Pulmonary arterial hypertension

Trial design

Design model

Single group

Treatments tested in this trial

  • Dasatinib and quercetin

    Drug

    Participants will receive 100 mg of dasatinib and 1250 mg of quercetin orally once a day for 2 days every 2 weeks over 12 consecutive weeks

Treatment groups

30 Participants
are divided into 1 treatment group
Group A: TreatmentExperimental treatment 1 intervention

Trial outcomes

Primary outcomes

1

Participant retention rate

Participant retention rate with D+Q therapy with no more than one missed study visit

Time frame
Baseline until 3 months
2

Recruitment feasibility

The number of subjects screened to identify eligible participants

Time frame
Baseline
3

Frequency of adverse drug effects of dasatinib and quercetin

Frequency of adverse drug effects of dasatinib and quercetin

Time frame
From baseline through study completion at 1 year

Secondary outcomes

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Ohio State University

Lead sponsor

Source ClinicalTrials.gov

This trial is not recruiting at the moment. You can still explore other options: